Sinco Pharmaceuticals Holdings Limited provides group earnings guidance for the year ended 31 December 2022. For the year, the group is expected to record a net profit attributable to equity holders of the Company for the Current Year of approximately RMB 68.0 million, representing a decrease of approximately RMB 67.1 million or approximately 49.7%, as compared to the net profit attributable to equity holders of the Company of approximately RMB 135.1 million for the year ended 31 December 2021.